Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
最新の財務諸表(Form-10K)によると、Sol Gel Technologies Ltdの総資産は$35で、純損失は$-10です。
SLGLの主要な財務比率は何ですか?
Sol Gel Technologies Ltdの流動比率は5.83、純利益率は-90.9、1株当たり売上高は$3.94です。
Sol Gel Technologies Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
Sol Gel Technologies Ltd の最大収益セグメントは Topical Dermatological Drug で、最新の利益発表における収益は 1,554,000 です。地域別に見ると、Israel が Sol Gel Technologies Ltd の主要市場であり、収益は 1,554,000 です。
Sol Gel Technologies Ltdは収益を上げていますか?
いいえ、最新の財務諸表によると、Sol Gel Technologies Ltdの純損失は$-10です。